Top

International Journal of Clinical Oncology

Published in:

01-04-2019 | Original Article

Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer

Authors: Takeshi Kawaguchi, Noriyoshi Sawabata, Sachiko Miura, Norikazu Kawai, Motoaki Yasukawa, Takashi Tojo, Shigeki Taniguchi

Published in: International Journal of Clinical Oncology | Issue 4/2019

Abstract

Background

Pulmonary wedge resection is an option for lung cancer patients with limited cardiopulmonary preservation. As the impact of underlying lung status on the prognosis of such patients remains unclear, we assessed this issue.

Methods

A total of 149 borderline surgical candidates with localized lung cancer who had undergone wedge resection were retrospectively investigated. Clinical variables related to perioperative morbidity, local control rate, and oncological outcomes based on underlying lung disease were analyzed.

Results

According to the risk analysis of postoperative complications, underlying lung disease did not influence the surgical morbidity. Postoperative recurrence occurred in 65 patients (locoregional recurrence in 36, distant metastasis in 12, and both simultaneously in 17). Multivariate analysis revealed that emphysema on computed tomography (CT) [hazard ratio (HR) 0.45; 95% confidence interval (CI) 0.21–0.99] was an independent indicator of locoregional recurrence. Forty-four patients died of lung cancer and 29 of other causes. Multivariate analysis demonstrated that interstitial lung disease on CT (HR 1.98; 95% CI 1.01–3.89) was a predictor of poor prognosis.

Conclusion

Pulmonary wedge resection can be safely undergone by lung cancer patients regardless of pulmonary comorbidity, although underlying lung disease may influence the prognosis after wedge resection.

El-Sherif A, Gooding WE, Santos R et al (2006) Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg 82:408–416CrossRefPubMed

Dziedzic R, Żurek W, Marjański T et al (2017) Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish national lung cancer registry. Eur J Cardiothorac Surg 52:363–369CrossRefPubMed

Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076CrossRefPubMedCentralPubMed

Iwata H, Murakami M, Demizu Y et al (2010) High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 116:2476–2485PubMed

Crabtree T, Puri V, Timmerman R et al (2013) Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG0236), sublobar resection (ACOSG Z4032), and radiofrequency ablasion (ACOSOG Z4033). J Thorac Cardiovasc Surg 145:692–699CrossRefPubMed

Ueki N, Matsuo Y, Togashi Y et al (2015) Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 10:116–125CrossRefPubMed

Zheng A, Wang X, Yang X et al (2014) Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg 98:243–248CrossRefPubMed

Sawabata N, Ohta M, Matsumura A et al (2004) Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg 77:415–420CrossRefPubMed

Sawabata N (2013) Locoregional recurrence after pulmonary sublobar resection of non-small cell lung cancer: can it be reduced by considering cancer cells at the surgical margin? Gen Thorac Cardiovasc Surg 61:9–16CrossRefPubMed

10.

Mohiuddin K, Haneuse S, Sofer T et al (2014) Relationship between margin distance and local recurrence among patients undergoing wedge resection for small (≤ 2 cm) non-small cell lung cancer. J Thorac Cardiovasc Surg 147:1169–1177CrossRefPubMed

11.

Hansell DM, Bankier AA, MacMahon H et al (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246:697–722CrossRefPubMed

12.

Lewis RJ, Caccavale RJ, Sisler GE et al (1992) Video-assisted thoracic surgical resection of malignant lung tumors. J Thorac Cardiovasc Surg 104:1679–1687PubMed

13.

Clavein PA, Barkun J, Oliveira ML et al (2009) The Clavien–Dindo classification of surgical complications. Ann Surg 250:187–196CrossRef

14.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed

15.

Rosen JE, Keshava HB, Yao X et al (2016) The natural history of operable non-small cell lung cancer in the national cancer center database. Ann Thorac Surg 101:1850–1855CrossRefPubMed

16.

Olsen GN (2000) Pulmonary physiologic assessment of operative risk. In: Shields TW, LoCicero III, Ponn RB (eds) General thoracic surgery, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 297–313

17.

Voltolini L, Bongiolatti S, Luzzi L et al (2013) Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg 43:e17–e23CrossRefPubMed

18.

Zhai R, Yu X, Shafer A et al (2014) The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. CHEST 145:346–353CrossRefPubMed

19.

Mimae T, Suzuki K, Tsuboi M et al (2015) Surgical outcomes of lung cancer in patients with combined pulmonary fibrosis and emphysema. Ann Surg Oncol 22:S1371–S1379CrossRefPubMed

20.

Sato T, Teramukai S, Kondo H et al (2014) Impact and predictors of acute exacerbation of interstitial lung disease after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 147:1604–1611CrossRefPubMed

21.

Wolf AS, Swanson SJ, Yip R et al (2017) The impact of margins on outcomes after wedge resection for stage I non-small cell lung cancer. Ann Thorac Surg 104:1171–1178CrossRefPubMed

22.

Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operative stage I non-small-cell lung cancer: a pooled analysis of two randomized trials. Lancet Oncol 16:630–637CrossRefPubMedCentralPubMed

23.

Nagata Y, Hiraoka M, Shibata T et al (2015) Prospective trials of stereotactic body radiation therapy for both operative and inoperative T1N0M0 Non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys 93:989–996CrossRefPubMed

24.

Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol 8:823–859CrossRefPubMedCentralPubMed

25.

Jeremic B, Bamberg M (2002) External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection. Radiother Oncol 64:251–257CrossRefPubMed

26.

Takeda A, Suzuki N, Eriguchi T et al (2013) Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer. Ann Thorac Surg 96:1776–1782CrossRefPubMed

27.

Ajmani GS, Wang CH, Kim KW et al (2018) Surgical quality of wedge resection affects overall survival in patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg 156:380–391CrossRefPubMed

28.

Sverzellati N, Guerci L, Randi G et al (2011) Interstitial lung disease in a lung cancer screening trial. Eur Respir J 38:392–394CrossRefPubMed

Title: Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer
Authors: Takeshi Kawaguchi
Noriyoshi Sawabata
Sachiko Miura
Norikazu Kawai
Motoaki Yasukawa
Takashi Tojo
Shigeki Taniguchi
Publication date: 01-04-2019
Publisher: Springer Singapore
Published in: International Journal of Clinical Oncology / Issue 4/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1367-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population

Histologic transformation of non-small-cell lung cancer in brain metastases

Verification of the diagnostic strategy for anterior mediastinal tumors

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial

Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer